Last €3.89 EUR
Change Today -0.01 / -0.26%
Volume 1.0
ALQGC On Other Exchanges
EN Paris
As of 3:00 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

quantum genomics sas-regr (ALQGC) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/11/14 - €6.59
52 Week Low
08/12/14 - €3.76
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

quantum genomics sas-regr (ALQGC) Related Businessweek News

No Related Businessweek News Found

quantum genomics sas-regr (ALQGC) Details

Quantum Genomics Corp., a biopharmaceutical research company, develops treatments in the field of cardiovascular diseases. The company develops products for cardiovascular diseases, including hypertension and heart failure. It also focuses on developing a therapeutic approach based on Brain Aminopeptidase A Inhibition (BAPAI). The company is based in Paris, France.

6 Employees
Last Reported Date: 04/8/14

quantum genomics sas-regr (ALQGC) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

quantum genomics sas-regr (ALQGC) Key Developments

Quantum Genomics SA(ENXTPA:QGCNR) added to Next Biotech Index

Quantum Genomics SA will be added to the Next Biotech Index.

Quantum Genomics SA, Annual General Meeting, Jun 30, 2014

Quantum Genomics SA, Annual General Meeting, Jun 30, 2014.

Quantum Genomics Announces Management Changes

Quantum Genomics announced the appointment of Marc Karako and Dr. Jean Philippe Milon as CFO and COO respectively. Both positions will support Lionel Ségard, chairman and CEO, and Fabrice Balavoine, vice president Research & Development, strengthening the management team of the company. Karako has previously served as group CFO and EVP of Carlson Wagonlit Travel, he was also group chief financial and legal officer of Vallourec and vice president finance at Thomson. Additionally he held various financial management positions at IBM Europe from 1985 to 1995. Dr. Milon served in various management positions at local and international level at Bayer where he was involved in primary care and cardiology, he joined the executive committee of Bayer to lead the global operations of mergers and acquisitions, licensing and business development. Additionally he managed the cardiovascular franchise of Sandoz. In his new role at Quantum Genomics, Dr. Milon will be responsible for the business development strategy of whose objective is to conclude, during phase 2, a partnership agreement with a pharmaceutical company regarding QGC001, its first in class drug candidate for the treatment of hypertension. Call Send SMS Add to Skype You'll need Skype CreditFree via Skype.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALQGC:FP €3.89 EUR -0.01

ALQGC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ALQGC.
View Industry Companies

Industry Analysis


Industry Average

Valuation ALQGC Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact QUANTUM GENOMICS SAS-REGR, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at